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Abstract
Hepatocyte nuclear factor 1β (HNF1β) is an essential transcription factor in devel-
opment of the kidney, liver, and pancreas. HNF1β-mediated transcription of target 
genes is dependent on the cell type and the development stage. Nevertheless, the reg-
ulation of HNF1β function by enhancers and co-factors that allow this cell-specific 
transcription is largely unknown. To map the HNF1β interactome we performed mass 
spectrometry in a mouse kidney inner medullary collecting duct cell line. Pterin-4a-
carbinolamine dehydratase 2 (PCBD2) was identified as a novel interaction partner 
of HNF1β. PCBD2 and its close homolog PCBD1 shuttle between the cytoplasm and 
nucleus to exert their enzymatic and transcriptional activities. Although both PCBD 
proteins share high sequence identity (48% and 88% in HNF1 recognition helix), their 
tissue expression patterns are unique. PCBD1 is most abundant in kidney and liver 
while PCBD2 is also abundant in lung, spleen, and adipose tissue. Using immunolo-
calization studies and biochemical analysis we show that in presence of HNF1β the 
nuclear localization of PCBD1 and PCBD2 increases significantly. Promoter lucif-
erase assays demonstrate that co-factors PCBD1 and PCBD2 differentially regulate 
the ability of HNF1β to activate the promoters of transcriptional targets important 
in renal electrolyte homeostasis. Deleting the N-terminal sequence of PCBD2, not 
found in PCBD1, diminished the differential effects of the co-factors on HNF1β 
activity. All together these results indicate that PCBD1 and PCBD2 can exert differ-
ent effects on HNF1β-mediated transcription. Future studies should confirm whether 
these unique co-factor activities also apply to HNF1β-target genes involved in ad-
ditional processes besides ion transport in the kidney.
K E Y W O R D S
hepatocyte nuclear factor 1β, pterin-4a-carbinolamine dehydratase 2, transcription co-factor
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1 |  INTRODUCTION
Hepatocyte nuclear factor 1β (HNF1β) is an essential tran-
scription factor for development and function of the kidney, 
liver, pancreas, and genital tract.1 Mutations or deletion in 
HNF1β cause autosomal dominant tubulointerstitial kidney 
disease subtype HNF1β (ADTKD-HNF1β), which is charac-
terized by renal malformations and cysts (80%), hypomagne-
semia (50%), maturity-onset diabetes of the young (MODY5) 
(40%), and genital tract malformations.2,3 Although the 
transcriptional targets are still being discovered, HNF1β-
regulated genes related to cyst development and ion transport 
in the kidney include PKHD1, PKD2, FXYD2, KCNJ16, and 
TMEM27.4-7
HNF1β exerts its function in homo- or heterodimeric 
complexes with HNF1⍺ and its activity is partially regu-
lated by binding to co-factors. In the past decades several 
HNF1β co-factors have been identified including p300/
CBP-associated factor (P/CAF), CREB-binding protein 
(CBP), two histone acetyltransferases (HAT), and histone 
deacetylase 1 (HDAC1).8,9 Moreover, the dimerization 
domain of HNF1β interacts with co-factor Pterin-4a-
carbinolamine dehydratase 1 (PCBD1) and forms heterote-
tramers in a 2:2 fashion.10 PCBD1 is part of an interesting 
group of multifunctional proteins called moonlighting 
proteins that fulfill multiple autonomous functions with-
out attributing these roles to different protein domains.11 
Next to its co-factor function, PCBD1 is localized in the 
cytosol where it forms homotetramers and regenerates 
tetrahydrobiopterin (BH4) together with dihydropteridine 
reductase.10,12 BH4 functions as a co-factor for phenylal-
anine hydroxylase (PAH) and other aromatic amino acid 
hydrolases.13 Interestingly, mutations in PCBD1 cause 
magnesium (Mg2+) wasting and diabetes, phenotypes also 
observed in patients with HNF1β mutations.14,15 Mg2+ 
wasting in these patients might be explained by the ability 
of PCBD1 to enhance HNF1β-mediated promoter activa-
tion of FXYD2, which is involved in Mg2+ reabsorption in 
the distal convoluted tubule (DCT).3,15
HNF1β controls the gene expression in epithelial cells 
of many organs, regulating a different set of target genes 
in every tissue.1 Moreover, in kidney development, HNF1β 
plays a recurring role during various stages regulating 
branching morphogenesis, collecting duct (CD) differen-
tiation, and tubular epithelial organization.16,17 This tis-
sue- and time-specific gene regulation of HNF1β might 
be explained by differential binding to and expression of 
co-factors.
In the current study, we aim to identify new interaction 
partners of HNF1β and to study their role in regulating HNF1β 
function. Mass spectrometry analysis of a mouse kidney cell 
line reveals PCBD2, a homolog of PCBD1, as a novel bind-
ing partner of HNF1β. Furthermore, the differential effects of 
the two dimerization factors on HNF1β-mediated gene tran-
scription of genes involved in renal electrolyte handling are 
uncovered.
2 |  MATERIALS AND METHODS
2.1 | Cell culture
Mouse inner medullary collecting duct (mIMCD3) Flp-in 
cells were grown in DMEM/F-12 1:1 (Sigma-Aldrich, St. 
Louis, MO, USA) containing 10% FCS (v/v) (Biowest, 
Kansas City, MO, USA) and 1% (w/v) sodium pyruvate at 
37°C in a humidity-controlled incubator with 5% (v/v) CO2. 
Human Embryonic Kidney (HEK293) cells were grown 
in DMEM (Lonza, Basel, Switzerland) containing 10% 
(v/v) FCS, 0.1  mM nonessential amino acids, and 2  mM 
L-glutamine at 37°C in a humidity-controlled incubator with 
5% (v/v) CO2.
2.2 | DNA constructs
Human PCBD2 full length cDNA was amplified from a 
pDNR-LIB (clone IRAUp969E0391D, Source BioSciences, 
Nottingham, UK) using PCR and subcloned into a pCI-
Neo IRES mCherry expression vector. Human HNF1β full 
length cDNA was amplified from HNF1β pCMV-SPORT6 
(clone IRATp970A0421D, Source BioSciences) using PCR 
and subcloned into the pCDNA5_frt expression vector 
and myc-tagged at the NH2 terminal.
5 Human HA-HNF1β 
pCINEO, Flag-PCBD1 pCINeo, KCNJ16 promoter pGL3, 
and FXYD2 pGL3 vectors were generated previously.4,5,15 
Mutant PCBD1-T51S, PCBD2-S78T, and PCBD2 lack-
ing the amino (N)-terminus (AA 1-27) constructs were 
generated using the Q5 site-directed mutagenesis accord-
ing to the manufacturer's protocol (New England Biolabs, 
Ipswich, US).
2.3 | Generation of stable cell line
mIMCD3 Flp-in positive cells were preselected with 100 µg/mL 
zeocin (Thermo Fisher Scientific, Waltham, MA, USA) 
before transfection. Cells were seeded in 6-well plates and 
stably transfected with 1.5  µg pCDNA5_frt Myc-HNF1β 
or empty pCDNA5_frt and 1.5 µg pOG44 constructs using 
lipofectamine 3000 (Thermo Fisher Scientific) at a 1:3 DNA 
to lipofectamine ratio. Two days after transfection positive 
cells were selected with 600 µg/mL of hygromycin (Thermo 
Fisher Scientific). Positive colonies appeared after 2 weeks 
and were isolated and grown until confluency. Cells were 
maintained in presence of 400 µg/mL of hygromycin.
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2.4 | Nuclear and cytoplasmic 
extract isolation
Nuclear extracts from mIMCD3 Flp-in myc-HNF1β, mIMCD3 
Flp-in WT, or HEK293 cells were generated as described previ-
ously.18 In short, cells were washed twice with PBS before har-
vesting. Subsequently, cells were incubated in hypotonic buffer 
(10  mM KCl, 1.5  mM MgCl2, and 10  mM Hepes-KOH pH 
7.9) containing 0.15% (v/v) NP-40 (Roche, Basel, Switzerland) 
and protease inhibitors and homogenized using a type B pes-
tle (tight). Homogenized cells were centrifuged for 15  min-
utes at 3200  g to pellet nuclei. Supernatant was collected to 
obtain cytoplasmic protein extract. Nuclei were incubated with 
lysis buffer (420 mM NaCl, 20% (v/v) glycerol, 2 mM MgCl2, 
0.2 mM EDTA, and 20 mM Hepes-KOH/pH 7.9) containing 
0.1% (v/v) NP-40 and protease inhibitors for 1  hour at 4°C. 
Lysed nuclei were centrifugated for 30 minutes at 20 000 g at 
4°C to obtain nuclear protein extracts.
To generate nuclear pellet extracts, remaining pellets 
were solubilized by resuspension in four volumes of RIPA 
buffer (150 mM NaCl, 50 mM Tris pH 8.0, 1% (v/v) NP-40, 
5 mM MgCl2, and 10% (v/v) glycerol). Benzonase (Merck 
Millipore, Burlington, Massachusetts, USA) was added at 
1000 U per 100 µL nuclear pellet. Samples were incubated at 
37°C while shaking until the pellet disappeared. The extracts 
were cleared by centrifugation at 18 000 g for 15 minutes at 
4°C.
2.5 | Western blotting
Nuclear and cytoplasmic protein extracts from mIMCD3 
Flp-in myc-HNF1β and mIMCD3 Flp-in wild-type (WT) 
cells were denatured in Laemmli sample buffer (2% (v/v) 
SDS, 0.01% (w/v) bromophenol blue, 6% (v/v) glycerol, and 
60  mM Tris-HCl/pH 6.8) containing 100  mM of DTT for 
30 minutes at 37°C. Subsequently, samples were subjected to 
SDS-PAGE and used for immunoblotting. Rabbitanti-c-Myc 
(9E10, 1:500, Santa Cruz Biotechnology, CA, USA), Rabbit 
anti-HNF1β (SC-22840, 1:500, Santa Cruz Biotechnology), 
mouse anti-HA (1:5,000, 6E2, Cell signaling) or mouse anti-
Flag M2 (F1804, 1:5,000, Sigma-Aldrich) primary antibod-
ies and peroxidase-conjugated sheep anti-mouse (A6782, 
1:10,000; Sigma-Aldrich) and peroxidase-conjugated goat 
anti-rabbit (A4914, 1:10,000; Sigma-Aldrich) secondary an-
tibodies were used to visualize proteins.
2.6 | Myc pull-down and sample 
preparation for Mass spectrometry
Nuclear extracts from mIMCD3 Flp-in myc-HNF1β and 
mIMCD3 Flp-in WT cells were subjected to Myc-affinity 
enrichment using Myc-Trap beads (ChromoTek, Planegg-
Martinsried, Germany). Three pull-downs were performed 
for each sample. Each pull-down, consisting of 1 mg of nu-
clear extract or 800 µg of nuclear pellet extract, was incubated 
with beads in incubation buffer (300 mM NaCl, 0.1% (v/v) 
NP-40, and 0.5 mM DTT 20 mM HEPES-KOH/pH7.9) for 
90 minutes on a rotating wheel at 4°C. Ethidium bromide was 
added to the pull-down reaction (10 mg/mL) to prevent indi-
rect, DNA-mediated interactions. Subsequently, beads were 
washed two times with incubation buffer containing 0.5% 
(v/v) NP-40, two times with PBS containing 0.5% (v/v) NP-
40, and lastly two times with only PBS. After washing, the 
supernatant was removed completely and precipitated pro-
teins were subjected to on-bead trypsin digestion as described 
previously.19 Beads were resuspended in 50 µL elution buffer 
(2 M Urea, 10 mM DTT, and 100 mM Tris-HCl/pH 8) and in-
cubated on a shaker for 20 minutes at room temperature (RT) 
to partly denature the proteins. Subsequently, iodoacetamide 
(Sigma-Aldrich) was added to the beads to a final concentra-
tion of 50 mM and incubated in the dark for 10 minutes on a 
shaker at RT to alkylate cysteines. After alkylation, 0.25 mg 
of trypsin (Promega, Madison, WI, USA) was added to the 
beads for 2 hours, shaking at RT to digest proteins from the 
beads. The supernatant was collected. To collect all peptides 
from the beads, another 50 µL of elution buffer was added 
to the beads and incubated for 5 minutes at RT, supernatant 
was collected and combined with the first supernatant. To 
ensure complete digestion of the proteins, 0.1 mg of trypsin 
was added to the supernatant and incubated overnight at RT. 
Next morning, digestion was stopped by adding trifluoro-
acetic acid (TFA) 0.5% (v/v). Tryptic peptides were loaded 
on C18 Stage tips as described previously.20 Briefly, C18 
Stage tips were washed with 50 µL of MeOH followed by 
buffer B (80% Acetonitrile, 0.1% v/v TFA), and two times 
buffer A (0.1% v/v TFA). Samples were loaded on stage tips 
by spinning for 10 minutes at 2400 g. Finally, loaded stage 
tips were washed twice with buffer A.
2.7 | Mass spectrometry and data analysis
Peptides were analyzed on reverse phase Easy-nLC 1000 
coupled on-line to a Thermo Q-Exactive hybrid mass spec-
trometer (Thermo Fisher Scientific) using a 120-minute gra-
dient of buffer B (80% Acetonitrile, 0.1% v/vTFA). Dynamic 
exclusion was enabled for 30 seconds.
Raw data were analyzed using the MaxQuant software 
suit,21 using the default settings, trypsin as protease and 
the Mus musculus database. Label-free quantification 
and intensity-based absolute quantification (iBAQ) were 
enabled. The resulting protein groups file was further 
processed using Perseus.22 The data were filtered for po-
tential contaminants and reverse hits. Then, triplicates were 
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assigned to the control or test group. Data were logarith-
mized and proteins were then filtered to contain at least 
three valid values in one of the groups, assuming that a 
specific interactor may not have been identified in the con-
trol pull-downs. Missing values were imputed using the 
default settings. Statistical outliers for the Myc pull-down 
of the mIMCD3 Flp-in myc-HNF1β compared to mIMCD3 
Flp-in WT were then determined using a two-tailed t test. 
Multiple testing correction was applied using a permuta-
tion-based false discovery rate (FDR) method in Perseus. 
Stoichiometry calculations are essentially as described.23 
The average iBAQ value obtained in the control pull-downs 
was subtracted from the iBAQ values obtained in each of 
the specific pull-downs. These values were then divided 
by the values of the bait protein in that pull-down. The 
remaining values were averaged and standard deviations 
were calculated. Data were visualized using the program R.
2.8 | Co-immunoprecipitation
HEK293 cells were seeded on 145  mm petri dishes and 
co-transfected with 20  µg Flag-PCBD1 or Flag-PCBD2 
constructs with 20  µg HA-HNF1β construct or an empty 
pCINeo IRES mCherry vector using lipofectamine 2000 
(Thermo Fisher Scientific) at a 1:1 DNA to lipofectamine 
ratio. Cells were harvested 48 hours after transfection and 
nuclear extracts were prepared as described above. The 
next incubation steps were all preformed under rotary agi-
tation. A total of 25 µL A/G of PLUS-Agarose beads (Santa 
Cruz Biotechnology) were previously incubated overnight 
at 4°C with 1  µL of mouse anti-HA antibody (6E2, Cell 
Signaling Technology, Danvers, MA, USA). Beads were 
washed one time with PBS to remove the unbound antibod-
ies. To bind antibodies covalently to the beads, beads were 
washed three times with 0.1 M of sodium borate-HCl/pH 
9.3 and incubated for 30 minutes with 0.1 M of sodium bo-
rate containing 20 mM of DMP at RT. Subsequently, fresh 
0.1 M of sodium borate containing 20 mM dimethyl pime-
limidate (DMP, Sigma-Aldrich) was added and incubated 
for 15 minutes at RT. After incubation beads were washed 
four times with 50  mM of glycine-HCl/pH 2.5 and once 
with 0.2 M of Tris-HCl/pH 8.0. Beads were neutralized in 
0.2 M of Tris-HCl/pH 8.0 for 2 hours at RT. After incuba-
tion Tris-HCl was removed and beads were resuspended in 
PBS to make a 1:1 slurry. After sampling the input control, 
equal amounts of protein of the remaining samples were 
incubated with the antibody beads overnight at 4°C. Next 
day beads were washed twice with incubation buffer (0.1% 
(v/v) NP-40) and twice with PBS. Samples were incubated 
for 30 minutes at 37°C in Laemmli sample buffer supple-
mented with 100 mM of DTT to separate the proteins from 
the beads. Proteins were detected by immunoblotting using 
mouse anti-HA (1:5000, 6E2, Cell signaling) or mouse 
anti-Flag M2 (F1804, 1:5000, Sigma-Aldrich) primary an-
tibodies and peroxidase-conjugated sheep anti-mouse sec-
ondary antibodies (A6782, 1:10 000; Sigma-Aldrich).
2.9 | Immunocytochemistry
HEK293 cells were seeded in 12-well plates on fibronec-
tin-coated glass coverslips and co-transfected with 666 ng 
HA-HNF1β or empty constructs with 333 ng Flag-PCBD1 
or Flag-PCBD2 or empty constructs using lipofectamine 
2000 (Thermo Fisher Scientific) at a 1:2 DNA to lipo-
fectamine ratio. After 48 hours, cells were fixated with 4% 
(v/v) paraformaldehyde for 10  minutes followed by per-
meabilization for 10 minutes with 0.3% (v/v) Triton X-100 
in PBS and finally incubated in blocking buffer for 30 min-
utes (16% (v/v) goat serum and 0.3% (v/v) Triton X-100 in 
PBS). Subsequently, fixed cells were incubated overnight 
at 4°C with a rabbit anti-Flag M2 antibody (F7425, 1:100, 
Sigma-Aldrich) and/or a mouse anti-HA antibody (1:100, 
6E2, Cell signaling) diluted in blocking buffer. Next day 
cells were washed three times with PBS and incubated with 
secondary antibodies goat anti-rabbit antibody coupled to 
Alexa Fluor 647 (A32733, 1:300, Thermo Fisher Scientific) 
or goat anti-mouse coupled to Alexa Fluor 594 (A11005, 
1:300, Thermo Fisher Scientific) or 488 (A-11029, 1:300, 
Thermo Fisher Scientific) together with 0.1  µg/mL of 
DAPI (D1306, Thermo Fisher Scientific) for 45 minutes at 
RT. Cells were washed three times with PBS and mounted 
with Fluoromount-G (Southern Biotech, Birmingham, AL, 
USA). Images were taken with a Zeiss LSM880 confocal 
microscope (Zeiss, Sliedrecht, The Netherlands) at 63x 
magnification. Images were analyzed using the software 
ImageJ.
2.10 | Immunohistochemistry
Stainings were performed on 3  µm sections of formalin-
fixed, paraffin-embedded healthy human kidney tissue. For 
all staining protocols, paraffin sections were deparaffinized 
and rehydrated. Subsequently, sections were heat-treated 
with sodium-citrate-HCl/pH 6.0 and washed three times in 
0.15 M of NaCl and 0.1 M of Tris-HCl/pH 7.6 (TN-buffer). 
Sections were permeabilized in TN-buffer containing 0.1% 
(v/v) Triton for 15  minutes. Endogenous peroxidase ac-
tivity was blocked with 0.3% (v/v) H2O2 and unspecific 
binding sites were blocked with blocking buffers (Avidin/
Biotin Blocking kit, BioLegend, San Diego, CA, USA). 
The sections were incubated with primary antibodies rabbit 
anti-PCBD2 (1:50, 200622-T08, Sino Biological, Vienna, 
Austria) overnight at 4°C. PCBD2 staining was enhanced 
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using TSA fluorescence System (PerkinElmer). In order to 
co-stain PCBD2 with nephron markers, sections were in-
cubated with the following primary antibodies for 4 hours 
at RT: guinea pig anti-AQP2 (1:200, home-made), sheep 
anti-UMOD (1:200, 8595-0054, Bio-Rad AbD Serotec, 
Hercules, CA, USA), and sheep anti-NCC (1:200). Human 
sections were incubated with Alexa Fluor 594 secondary 
antibodies (Thermo Fisher Scientific). Finally, sections 
were washed, incubated for 5 minutes with 0.1 µg/mL of 
DAPI (D1306, Thermo Fisher Scientific) and mounted 
with Fluoromount-G (Southern Biotech). Images were 
taken with an AxioCam MRm camera (Zeiss, Sliedrecht, 
The Netherlands) at 40x magnification. Zeiss Zen 2012 
(Zeiss) software was used to acquire the images.
2.11 | Luciferase reporter assay
HEK293 cells were seeded in 24-well plates and trans-
fected with 350  ng of the promoter firefly luciferase con-
structs (pGL3) previously generated containing the promoter 
of FXYD2, KCNJ16, or no promoter.4,5 All three con-
structs were co-transfected with 25  ng of pCINEO-empty 
or pCINEO-hHNF1B combined with pCINEO-empty, 
pCINEO-PCBD1, pCINEO-PCBD2, pCINEO-PCBD1-
T51S, pCINEO-PCBD2-S78T, or pCINEO-PCBD2-Δ1-27 
constructs. Additionally, for controlling the transfection 
efficiency in each reaction, 10 ng of Renilla luciferase con-
struct (pRL) under a CMV promoter was co-transfected and 
used to normalize luciferase counts in all conditions. Co-
transfections were performed using polyethylenimine cati-
onic polymer (PEI) (Thermo Fisher Scientific) in 1:6 DNA 
to PEI ratio. Firefly and Renilla luciferase luminescence were 
measured 48 hours after transfection with the dual-luciferase 
reporter assay (Promega) using a plate reader (VICTOR, 
PerkinElmer).
2.12 | Homology modeling of HNF1β 
interaction domain
No 3D-structure of the interaction domain of HNF1β is 
known. Therefore, we decided to build a homology model 
of residue 3-30 of HNF1β using PDB file 1F93 as template.5 
The fast YASARA24 and WHAT IF25 modeling script was 
used to create this model. This short stretch of residues shows 
67% sequence identity. The model was superposed on PDB 
file 1F93 and 4C45 (not yet published) to obtain the final 
PCBD1/2––HNF1β complex.
2.13 | Real-time quantitative PCR
Tissues from C57BL/6N mice were isolated and total RNA 
was extracted from the tissues using TRIzol reagent (Thermo 
Fisher Scientific) according to the manufacturer's proto-
col.26 The isolated RNA was subjected to DNase treatment 
(Promega). Subsequently, RNA was used for reversed tran-
scription using the M-MLV protocol described by the manu-
facturer (Thermo Fisher Scientific). Obtained cDNA was 
used to determine gene expression levels by SYBR Green 
(Bio-Rad) real-time PCR using the CF96 real-time PCR de-
tection system (Bio-Rad) and primers are listed in Table 1. 
mRNA levels were normalized for glyceraldehyde 3-phos-
phate dehydrogenase (Gapdh) expression.
2.14 | Statistical analysis (non-mass 
spectrometry experiments)
Data are expressed as means ± SD of at least three independ-
ent experiments. Differences were identified using Students t 
tests or two-way analysis of variance with correction for mul-
tiple testing using the Holm-Sidak procedure. P <  .05 was 
considered to be statistically significant.
3 |  RESULTS
3.1 | Co-factor PCBD2 interacts with 
HNF1β in the nucleus
To identify the co-factors that regulate HNF1β function, 
mass spectrometry analysis was performed in kidney cells 
to identify the interaction partners of HNF1β. Therefore, a 
mouse inner medullary collecting duct (mIMCD3) Flp-in 
cell line stably expressing Myc-HNF1β was generated 
(Figure S1A,B). Affinity purifications of Myc-HNF1β on 
T A B L E  1  Primer sequences
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nuclear extracts (NE) resulted in the identification of seven 
significant interactors, including PCBD2 (Figure 1A). Two 
known, previously identified interaction partners; HNF1⍺ 
and PCBD1 were present among the proteins, validating 
our experimental setup (Figure  1A).10,27 DNA pellets re-
maining after nuclear protein extraction were digested with 
nucleases to enable the extraction of proteins that bind 
to the DNA with high affinity. Similar to the NE, in the 
nuclear pellet extracts (NPE), we identified six interacting 
proteins, including PCBD1 and PCBD2, but not HNF1⍺ 
(Figure  1B). PCBD1 showed a stoichiometry relative to 
HNF1β of 1 and 0.42 in the NE and NPE samples, respec-
tively (Figure  1C,D). A stoichiometry of approximately 
0.01 was calculated for HNF1⍺, suggesting that in 1% of 
the complexes HNF1β forms heterodimers with HNF1⍺. 
Furthermore, PCBD2 demonstrated a stoichiometry of 0.12 
F I G U R E  1  Co-factor PCBD2 interacts with transcription factor HNF1β. A,B, Nuclear extracts (NE) and nuclear pellet extracts (NPE) from 
mIMCD3 Flp-in Myc-HNF1β transgenic cell lines and mIMCD3 Flp-in WT cells are subjected to single-step Myc-affinity enrichment using Myc-
Trap beads in triplicate. Statistically enriched proteins in the Myc pull-down are identified by permutation-based FDR-corrected t test. The intensity 
of the proteins in the Myc pull-down over the control is plotted against the −log10 P value and the red line indicates the permutation-based 
FDR threshold (thresholds NE: P value <.0001 and log2(FC) > 1.4 and thresholds NPE: P value <.01 and log2(FC) > 2.5). C,D, Stoichiometry 
calculations of the statistically significant interactors of Myc-HNF1β. Stoichiometry of the interactors is determined by calculating the abundance 
of the interactors in the specific pull-down (iBAQ value). The iBAQ values obtained in the control samples (WT mIMCD3 Flp-in cells) are 
subtracted from the iBAQ intensity in the Myc pull-down. The remaining values were scaled according to the abundance of Myc-HNF1β, resulting 
in the stoichiometry of the interactors relative to the bait. E, Flag-tagged PCBD1 or PCBD2 or mock DNA were transiently expressed in HEK293 
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and 0.02 relative to HNF1β in the NE and NPE, respec-
tively. The HNF1β-PCBD2 interaction was validated by 
coimmunoprecipitation assays in HEK293 cells transfected 
with constructs for HNF1β and PCBD2 using PCBD1 as 
control (Figure 1E).
3.2 | PCBD1 and PCBD2 translocate to the 
nucleus in presence of HNF1β
In the cytoplasm, PCBD1 and PCBD2 facilitate an en-
zymatic function in tetrahydrobiopterin recycling.12,28 
However, in the nucleus the proteins act as co-factors for 
HNF1⍺ and HNF1β transcriptional activity. To study the 
cellular localization of PCBD1 and PCBD2, nuclear and 
cytoplasmic extracts were prepared of HEK293 cells trans-
fected with PCBD1 or PCBD2 together with a mock or 
HNF1β construct and analyzed by Western blot analysis. 
As expected, HNF1β was exclusively present in the nu-
clear extracts (Figure 2A). In absence of HNF1β, PCBD1 
and PCBD2 were predominantly present in the cytoplas-
mic extracts (Figure 2A). Conversely, quantification of the 
Western blots showed a 55% and 41% increase in nuclear 
localization of PCBD1 and PCBD2, respectively, as result 
of co-transfection with HNF1β (Figure 2B). Moreover, lo-
calization studies using immunocytochemistry in HEK293 
cells demonstrated expression of PCBD2 in the nucleus 
and cytosol (Figure  2C). Co-transfection of PCBD2 and 
HNF1β increased nuclear localization of PCBD2 compared 
to cells only expressing PCBD2 (Figure  2D). Similar re-
sults were observed for PCBD1 (Figure 2C,D).
3.3 | PCBD2 and its close homolog PCBD1 
display unique tissue expression patterns
The expression of Pcbd1 and Pcbd2 was examined in a 
mouse tissue panel by RT-qPCR to study tissue expression 
patterns of these highly related proteins. Pcbd1 mRNA was 
predominantly expressed in kidney and liver while Pcbd2 
was also robustly expressed in lung, spleen, and fat tissue 
(Figure  3A). Additionally, mRNA levels of transcription 
factor Hnf1b and Hnf1a were measured in the mouse tissue 
panel. Hnf1b is primarily expressed in kidney, lung, and 
colon while Hnf1a is expressed in kidney, liver, and small 
intestines (Figure 3B).
HNF1β is expressed along the whole nephron and is im-
portant for kidney function.1 To evaluate the localization 
F I G U R E  2  Co-factor PCBD1 and 
PCBD2 translocate to the nucleus in 
presence of HNF1β. A, Flag-tagged PCBD1 
or PCBD2 or mock DNA was transiently 
expressed in HEK293 cells together with 
HA-tagged HNF1β. Nuclear extracts (NE) 
and cytoplasmic extracts (CE) were prepared 
and analyzed by Western blots (WB) 
using anti-HA and anti-Flag antibodies. B, 
Quantification of Western blots using FIJI 
image processing. Black bars represent 
data of PCBDs co-transfected with mock 
DNA and white bars represent PCBDs 
co-transfected with HNF1β. Data represents 
three independent experiments ± SD. 
* P < .05. C, Immunocytochemistry 
analysis of HEK293 transfected with HA-
HNF1β or Flag-PCBD1 or Flag-PCBD2 
constructs. Scale bar represents 10 µm. D, 
Immunocytochemistry analysis of HEK293 
co-transfected with HA-HNF1β and Flag-
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of PCBD2 in the kidney, immunohistochemical analysis 
of healthy human kidney tissue was performed. PCBD2 
staining was most abundant in the outer medulla and co-lo-
calized with uromodulin (UMOD), a marker for the thick 
ascending loop of Henle (TAL) (Figure  3C). In addition, 
PCBD2 co-localized with Na+/Cl− cotransporter (NCC) 
in the DCT (Figure  3D). We detected no expression of 
PCBD2 in the CD, using Aquaporin 2 (AQP2) as a marker 
(Figure 3E).
3.4 | PCBD2 mediates HNF1β promoter 
activation different from PCBD1
To examine whether PCBD2 regulates the transcriptional 
activity of HNF1β, a dual luciferase promoter assay was 
performed. HEK293 cells were co-transfected with lu-
ciferase constructs, containing the promoter of FXYD2 
or KCNJ16, which are known transcriptional targets of 
HNF1β in the kidney.4,5 Promoter activation of Na+/K+ 
F I G U R E  3  PCBD2 and PCBD1 
display unique tissue expression patterns. A, 
Pcbd1 (black bars) and Pcbd2 (white bars) 
mRNA levels were measured in a mouse 
tissue panel by RT-PCR and normalized to 
Gapdh expression. B, Hnf1a (black bars) 
and Hnf1β (white bars) mRNA levels were 
measured in a mouse tissue panel by RT-
PCR and normalized to Gapdh expression. 
Data represents three independent 
experiments ± SD. * P < .05. Human 
kidney tissues were co-stained for PCBD2 
(green), (C) NCC (red), (D) UMOD (red), 
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ATPase subunit gamma (FXYD2) was increased by 52% 
in the presence of co-factor PCBD1, while PCBD2 did 
not enhance promoter activation by HNF1β (Figure  4A). 
Promoter activation of KCNJ16, encoding the inwardly 
rectifying K+ channel 5.1, did not increase in presence of 
PCBD1 (Figure 4B). In contrast, PCBD2 significantly de-
creased HNF1β-mediated promoter activation of KCNJ16 
by 42% (Figure 4B).
3.5 | “Kinetic hotspot” 
does not explain distinct co-factor activities of 
PCBD1 and PCBD2
The amino acid sequences of both mouse and human PCBD1 
and PCBD2 share 48% identity and have a similarity of 88% 
within the recognition helix (Figure S2A). The recognition 
helices of PCBD1 and PCBD2, responsible for HNF1 bind-
ing and homotetramerization, differ at three residues: 45R-
72Q, 51T-78S, and 61D-88N (Figure  5A,C). The major 
difference is located at the center of the recognition helix 
at residues 51 and 78 of PCBD1 and PCBD2, respectively 
(Figure 5A,C). The serine residue in PCBD2, correspond-
ing to T51 in PCBD1, allows a water molecule to be present 
within the homotetramer.28 This change results in low sta-
bility of the PCBD2 tetramer and, therefore, preferred asso-
ciation with HNF1⍺ molecules.28,29 The bulkier T51 residue 
of PCBD1 prevents a water molecule from binding, estab-
lishing a hyper stable tetrameric complex that does not form 
complexes with HNF1 in solution but requires co-folding 
of the two proteins.10,30,31 We hypothesized that this “ki-
netic hotspot” could affect the HNF1β activation properties 
of PCBD1 and PCBD2 (Figure 5A). To this end, constructs 
were generated expressing mutant PCBD1-T51S and the 
corresponding PCBD2-S78T mutant. Again, HEK293 cells 
were co-transfected with luciferase constructs, containing 
the FXYD2 promoter, with or without overexpression of 
HNF1β and PCBD1, PCBD2, PCBD1-T51S, or PCBD2-
S78T. HNF1β-mediated promoter activation of FXYD2 was 
not changed in presence of co-factor PCBD1 compared to 
PCBD1-T51S (Figure 5B). Similarly, the serine to threonine 
mutation in PCBD2 did not affect promoter activation by 
HNF1β compared to WT PCBD2 (Figure 5B).
3.6 | N-terminal sequence of PCBD2 is 
required for its co-factor function
The PCBD2 amino acid sequence contains an additional 27 
amino acids in the NH2 (N)-terminus that are not present 
in the PCBD1 sequence (Figure  5C). Using the PSIPRED 
server we could predict that part of this N-terminal strand 
likely forms an extra alpha helix (Figure 5C).32 We hypoth-
esized that the N-terminal sequence of PCBD2 might explain 
the differential activities of PCBD1 and PCBD2 regarding 
HNF1β co-activation. Therefore, constructs of PCBD2 were 
generated lacking the N-terminal amino acids from 1 to 27 
and luciferase assays were performed. Interestingly, FXYD2 
promoter activity mediated by HNF1β was significantly en-
hanced in the presence of PCBD2 lacking the 27 N-terminal 
amino acid sequence compared to WT PCBD2 (Figure 5D).
4 |  DISCUSSION
In the present study PCBD2 was identified as a novel in-
teraction partner of HNF1β. PCBD2 modulates HNF1β 
promoter activation of genes involved in electrolyte ho-
meostasis, different from PCBD1. Specifically, PCBD2 de-
creased promoter activity of KCNJ16 while PCBD1 did not 
alter HNF1β-mediated promoter activation. The FXYD2 pro-
moter showed increased activity in presence of PCBD1 while 
F I G U R E  4  HNF1β-mediated gene transcription is differently regulated by PCBD1 and PCBD2. A, HEK293 cells were transiently transfected 
with a luciferase construct carrying the human FXYD2 promoter, or a mock construct. Promoter activity was tested in presence or absence of 
HNF1βand with or without the presence of PCBD1 and PCBD2. B, HEK293 cells were transiently transfected with a luciferase construct carrying 
the human KCNJ16 promoter, or a mock construct. Promoter activity was tested in presence or absence of HNF1β and with or without the presence 
of PCBD1 and PCBD2. Data represents three independent experiments ± SD. * P < .05
(A) (B)
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PCBD2 did not affect FXYD2 promoter activity. Further 
studies should confirm whether the unique effects of PCBD1 
and PCBD2 on HNF1β activity can be extended to additional 
HNF1β-target genes involved in cystogenesis, kidney devel-
opment or intestinal function.
PCBD2 is classified as a moonlighting protein, as it par-
ticipates in two unrelated biological processes. In the cytosol 
PCBD2 mediates recycling of tetrahydrobiopterin, which is a 
co-factor for amino acid hydroxylases. Next to its enzymatic 
function PCBD2 has been described as a dimerization co-fac-
tor of HNF1⍺, however an interaction with HNF1β has not 
been reported before.28 The protein is homologous to PCBD1, 
in which mutations have previously been demonstrated to 
cause hyperphenylalaninemia, hypomagnesemia, and dia-
betes.28,33,34 Indeed, the interaction of PCBD1 with HNF1β 
was confirmed in our studies.10,15,27 Furthermore, multiple 
CD-specific genes were recognized in the pull-downs as well 
as genes known to be characteristic for other kidney seg-
ments including HNF1⍺ and KIM-1 that are thought to be 
expressed by the proximal tubule (PT) only.35-37 Interestingly, 
in contrast to the NE pull-down we did not identify HNF1⍺ 
among significant and nonsignificant interactors in the NPE 
pull-down. This finding indicates that PCBD2, like PCBD1, 
directly binds to HNF1β independently of HNF1⍺. However, 
F I G U R E  5  N-terminal sequence of PCBD2 is required for its co-factor function. A, Homology model of the PCBD1/2-HNF1β dimerization 
domain tetramer modeled using the structures of the PCBD1-HNF1⍺ dimerization domain (HNF1⍺-D) complex (Protein Data Bank ID code 
1F93) and the structure of PCBD2 (Protein Data Bank ID code 4C45). PCBD1 (gray), PCBD2 (blue), and HNF1β dimerization domain dimer (red/
orange). The side chain of residues T51 and S78 are shown in green and red, respectively. B, HEK293 cells were transiently transfected with a 
luciferase construct carrying the human FXYD2 promoter, or a mock construct. Promoter activity was tested in presence or absence of HNF1β and 
with or without the presence of PCBD1, PCBD2, PCBD1-T51S, or PCBD2-S78T. Data represents three independent experiments ± SD. * P < .05. 
C, Amino acid sequences of human PCBD1 and PCBD2 were aligned using the align tool of Uniprot. Green: Alpha helices, predicted by the 
PSIPRED server for PCBD2, Gray: Degree of sequence similarity, Red box: “kinetic hotspot.” D, HEK293 cells were transiently transfected with a 
luciferase construct carrying the human FXYD2 promoter, or a mock construct. Promoter activity was tested in presence or absence of HNF1β and 




   | 11 of 14THOLEN ET aL.
in both the NE and the NPE pull-down PCBD2 was found 
less frequently in complex with HNF1β compared to PCBD1. 
Remarkably, other studies using human fetal kidney and adult 
mouse kidney cells, identified additional HNF1β interaction 
partners including E4F1,38 TRM26,38 and Zyxin.39 The dif-
ferences between these studies indicate that distinct co-fac-
tors may interact with HNF1β depending on the renal cell 
type and stage of kidney development.
Despite their significant homology, our luciferase exper-
iments demonstrate that PCBD1 and PCBD2 have different 
effects on HNF1β-induced transcriptional activity. In pres-
ence of PCBD1, HNF1β-mediated promoter activation of 
FXYD2 was increased (52%), whereas it was unaltered by 
PCBD2. Additionally, we have performed HNF1β promoter 
luciferase assays with the KCNJ16 promoter in presence of 
PCBD1 for the first time. Surprisingly, PCBD1 did not in-
crease the HNF1β-induced promoter activation of KCNJ16 
as it does for the FXYD2 promoter. The KCNJ16 promoter 
activation was reduced (42%) in presence of PCBD2 while 
PCBD1 did not alter HNF1β function. The major difference 
in the recognition helices of PCBD1 and PCBD2 is located 
at residue 51 and 78, respectively.28,29,40 However, mutating 
this “kinetic hotspot” did not modulate their transcriptional 
activity. In contrast, deleting the N-terminal sequence of 
PCBD2, that is missing in the PCBD1 sequence, did increase 
HNF1β promoter activity compared to the activity observed 
in presence of the normal functioning PCBD2. The position 
of this alpha helix in the PCBD2 protein structure is pres-
ently unknown. Nevertheless, it could be hypothesized that 
this helix directly interacts with HNF1β or is essential for the 
recruitment of additional regulatory proteins.
Indeed, the saddle shaped surface of PCBDs is optimal for 
protein-protein binding. Previous studies demonstrated that 
mutagenesis of residues lining this concave shaped surface 
in PCBD1 decreased transcriptional activity of HNF1⍺.41 
Moreover, interactions with the co-factors may be specific for 
a PCBD isoform. For instance, Sirtuin 1 (SIRT1) deacetylates 
two lysine residues of PCBD2 (K124 and K131) that are not 
conserved in the PCBD1 sequence.42 Intestine-specific knock 
out of Sirt1 in mice led to decreased transcriptional activation 
of HNF1⍺/β-target gene Farnesoid X receptor (Fxr), likely 
through hyperacetylation of PCBD2.42,43 This modification 
might stabilize the homotetrameric form of PCBD2, thereby 
decreasing the formation of PCBD2-HNF1⍺ complexes.42 
Our interaction assay did not identify additional co-factors of 
transcriptional activity, which may suggest that these interac-
tions are transient.
As a consequence of the bifunctional role of PCBD1 and 
PCBD2 their localization is nuclear as well as cytoplasmic. 
We show that the nuclear localization of both PCBD1 and 
PCBD2 significantly increases in presence of HNF1β at the 
expense of the cytoplasmic localization. Interestingly, in our 
western blot analysis, the PCBD molecules were detected at a 
size ranging from 17 kDa to approximately 12 kDa, suggest-
ing that these proteins are posttranslationally modified both 
in the cytoplasmic and nuclear fractions. Notably, PCBD 
molecules in the immunoprecipitation fractions demonstrated 
a narrower size distribution compared to the input fraction, 
indicating that only a subset of the modified PCBD mole-
cules interact with HNF1β. These observations should be in-
terpreted with caution as we did not exclude the possibility 
that these distinctly sized proteins are degradation products 
of the co-factors. Nevertheless, the role of posttranslational 
modifications for the PCBD-HNF1β interaction would be in-
teresting subjects for future studies.
The distinct transcriptional activities of PCBD1 and 
PCBD2 provide a mechanism to differentially regulate 
HNF1β function. Indeed, our expression analysis demon-
strated that Pcbd1 and Pcbd2 expression is specific for dif-
ferent tissues. Whereas Pcbd1 predominantly is expressed in 
kidney and liver, Pcbd2 was also highly expressed in lung, 
spleen, and fat tissue. Within the kidney, immunohistochem-
ical analysis showed enrichment of the PCBD2 staining in 
the TAL and DCT, while a study from Ferrè et al15 reported 
PCBD1 protein expression primarily in the DCT. In contrast, 
transcriptomics data of rat and human kidney show mRNA 
expression of Pcbd1 in all renal tubules.37,44 Accordingly, 
proteomics data in rat reported expression of PCBD1 and 
PCBD2 in all epithelial cells of the kidney except the cells 
of the glomeruli.35 In contrast to our immunohistochemistry 
analysis, the expression of the PCBD molecules in PT cells 
was one of the highest.35 Although the data discussed here 
vary from human and mouse to rat, it is likely PCBD1 expres-
sion is not restricted to the DCT as observed by Ferrè et al.15 
Interesting to note is that most datasets described a 2- to 10-
fold higher expression of PCBD1 in renal tubules compared 
to PCBD2.35
Transcriptional targets of HNF1β in the TAL involved in 
electrolyte transport and cystogenesis are calcium-sensing 
receptor (CASR), PKHD1 and KCNJ16.4,6,45 In the DCT, 
FXYD2 and KCNJ16 are the main transcriptional targets. 
Interestingly, while both PCBD2 and PCBD1 are expressed 
in the DCT, our luciferase experiments show that PCBD1 
enhances the activation of the FXYD2 promoter by HNF1β 
while PCBD2 does not.15 These different transcriptional ac-
tivities of the PCBD molecules might explain why PCBD2 
cannot compensate for loss of PCBD1 function in patients 
with PCBD1 mutations. HNF1β is known to regulate many 
more genes involved in kidney function and development 
besides ion transport in the DCT and TAL. The function of 
PCBD1 and PCBD2 in HNF1β-mediated gene transcription 
could, therefore, be different for genes involved in cystogene-
sis, kidney development or intestinal function.
Interestingly, in our mouse tissue panel Pcbd1 and Pcbd2 
are expressed in spleen and fat while these tissues neither 
express Hnf1a or Hnf1b nor display PAH activity. Previous 
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studies in Xenopus showed that PCBD1 is expressed earlier in 
vertebrate development than HNF1⍺ and PAH.46 It was also 
found in skin, brain, and pigmented epithelium where no Hnf1a 
or Hnf1b expression was detected.46 In line with our findings 
this suggests an unknown function of PCBD1 and PCBD2 in 
these tissues, presumably binding to other transcription factor 
besides HNF1⍺ and HNF1β regulating their function.46,47
Our results showing that PCBD2 is a novel distinct regula-
tor of HNF1β activity, opens up new perspectives to study the 
heterogenic and complex HNF1β function. PCBD2 has been 
associated with tumor growth, type two diabetes, and osteopo-
rosis.48-51 Indeed, two GWAS studies identified risk variants in 
the PCBD2 gene, rs299371-T, and rs319598-C, that are asso-
ciated with whole bone mineral density and type two diabetes 
susceptibility.49,50 Given the central role of HNF1β in kid-
ney development, magnesium homeostasis, and diabetes, the 
PCBD2-HNF1β interaction may explain these associations.
In conclusion, our results provide an example of gene 
regulation by transcription factors mediated by different ex-
pression patterns and activities of co-factors. Specifically, we 
demonstrate that despite the high similarity in function and 
sequence of PCBD1 and PCBD2, the two co-factors are ca-
pable of modulating HNF1β transcriptional activity in a dif-
ferent fashion.
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